These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 4610119)

  • 1. Bioavailability of aminosalicylic acid and its various salts in humans IV: comparison of four brands of the sodium salt.
    Pentikäinen PJ; Wan SH; Azarnoff DL
    J Pharm Sci; 1974 Sep; 63(9):1431-4. PubMed ID: 4610119
    [No Abstract]   [Full Text] [Related]  

  • 2. Bioavailability studies on p-aminosalicylic acid and its various salts in man. II. Comparison of parasal and pascorbic.
    Pentikainen P; Wan SH; Azarnoff DL
    Am Rev Respir Dis; 1973 Dec; 108(6):1340-70. PubMed ID: 4751720
    [No Abstract]   [Full Text] [Related]  

  • 3. Importance of the type of dosage form and saturable acetylation in determining the bioactivity of p-aminosalicylic acid.
    Wagner JG; Holmes PD; Wilkinson PK; Blair DC; Stoll RG
    Am Rev Respir Dis; 1973 Sep; 108(3):536-46. PubMed ID: 4745249
    [No Abstract]   [Full Text] [Related]  

  • 4. Bioavailability of aminosalicylic acid and its various salts in humans. 3. Absorption from tablets.
    Wan SH; Pentikainen PJ; Azarnoff DL
    J Pharm Sci; 1974 May; 63(5):708-11. PubMed ID: 4829991
    [No Abstract]   [Full Text] [Related]  

  • 5. [The level of p-aminosalicyclic acid in the blood in oral treatment with a calcium-aluminum-p-aminosalicylate].
    Mulder RJ; Huizinga T
    Ned Tijdschr Geneeskd; 1968 Sep; 112(37):1630-4. PubMed ID: 4878452
    [No Abstract]   [Full Text] [Related]  

  • 6. Effect of food coadministration on 5-aminosalicylic acid oral suspension bioavailability.
    Yu DK; Elvin AT; Morrill B; Eichmeier LS; Lanman RC; Lanman MB; Giesing DH
    Clin Pharmacol Ther; 1990 Jul; 48(1):26-33. PubMed ID: 2369807
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Metabolism of PASA during administration of the preparation once and thrice daily].
    Savula MM
    Probl Tuberk; 1967; 45(4):70-4. PubMed ID: 5606807
    [No Abstract]   [Full Text] [Related]  

  • 8. The role of the metabolism of p-aminosalicylic acid (PAS) in the treatment of tuberculosis. Interaction with the metabolism of isonicotinic acid hydrazide (INH) and the synthesis of cholesterol.
    Lehmann J
    Scand J Respir Dis; 1969; 50(3):169-85. PubMed ID: 5195904
    [No Abstract]   [Full Text] [Related]  

  • 9. [Studies on the metabolism of para-aminosalicylic acid in the body. IV. Effect of sodium salt of para-animosalicylic acid administered orally in coated tablets soluble in the intestine on the bacteriostatic level and on drug tolerance].
    Hornung S; Nilodemowicz E; Owsiński J; Rapf T
    Gruzlica; 1967 Jul; 35(7):657-64. PubMed ID: 4865322
    [No Abstract]   [Full Text] [Related]  

  • 10. 5-aminosalicylic acid in a slow-release preparation: bioavailability, plasma level, and excretion in humans.
    Rasmussen SN; Bondesen S; Hvidberg EF; Hansen SH; Binder V; Halskov S; Flachs H
    Gastroenterology; 1982 Nov; 83(5):1062-70. PubMed ID: 7117789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Concentration in the blood and excretion of para-aminosalicylic acid and its metabolites after intake of BEPAS preparation].
    Savula MM
    Probl Tuberk; 1973; 51(10):44-7. PubMed ID: 4784037
    [No Abstract]   [Full Text] [Related]  

  • 12. Negligible excretion of 5-aminosalicylic acid in breast milk.
    Klotz U; Harings-Kaim A
    Lancet; 1993 Sep; 342(8871):618-9. PubMed ID: 8102746
    [No Abstract]   [Full Text] [Related]  

  • 13. Correlation of dissolution, disintegration, and bioavailability of aminosalicylic acid tablets.
    Schirmer RE; Kleber JW; Black HR
    J Pharm Sci; 1973 Aug; 62(8):1270-4. PubMed ID: 4725168
    [No Abstract]   [Full Text] [Related]  

  • 14. Intrarectal administration of 5-aminosalicylic acid to rabbits and dogs.
    Berryman EL; Zerouala AC; Meschter C; Spenard J
    Hum Exp Toxicol; 2002 Mar; 21(3):159-63. PubMed ID: 12102542
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolism and urinary excretion of 5-amino salicylic acid in healthy volunteers when given intravenously or released for absorption at different sites in the gastrointestinal tract.
    Myers B; Evans DN; Rhodes J; Evans BK; Hughes BR; Lee MG; Richens A; Richards D
    Gut; 1987 Feb; 28(2):196-200. PubMed ID: 3557190
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of the lymphatics in the intestinal absorption and distribution of drugs.
    De Marco TJ; Levine RR
    J Pharmacol Exp Ther; 1969 Sep; 169(1):142-51. PubMed ID: 4979680
    [No Abstract]   [Full Text] [Related]  

  • 17. Kinetics of 5-aminosalicylic acid after jejunal instillation in man.
    Haagen Nielsen O; Bondesen S
    Br J Clin Pharmacol; 1983 Dec; 16(6):738-40. PubMed ID: 6661362
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disposition of disodium azodisalicylate in healthy subjects. A possible new drug for inflammatory bowel disease.
    van Hogezand RA; van Hees PA; Zwanenburg B; van Rossum JM; van Tongeren JH
    Gastroenterology; 1985 Mar; 88(3):717-22. PubMed ID: 2857146
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rifampicin blood serum levels and half-life during prolonged administration in tuberculous patients.
    Nitti V; Delli Veneri F; Ninni A; Meola G
    Chemotherapy; 1972; 17(2):121-9. PubMed ID: 4558400
    [No Abstract]   [Full Text] [Related]  

  • 20. Capacity-limited gut wall metabolism of 5-aminosalicylic acid, a therapeutically active metabolite of sulfasalazine, in rats.
    Pieniaszek HJ; Bates TR
    J Pharm Sci; 1979 Oct; 68(10):1323-5. PubMed ID: 41931
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.